Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

Study Identifier:
LB-001LT
ClinicalTrials.gov Identifier:
NCT05506254
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: hLB-001
Date
Jul 2022 - Jan 2037
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Inclusion Criteria:
  • Participant has previously participated in a LogicBio clinical trial and received hLB-001.
  • Exclusion Criteria:
  • None
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: hLB-001
Date
Jul 2022 - Jan 2037
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Inclusion Criteria:
  • Participant has previously participated in a LogicBio clinical trial and received hLB-001.
  • Exclusion Criteria:
  • None

Protocol Summary

This is a non-interventional long-term follow-up study of patients who have participated in LogicBio studies for the treatment of MMA and received hLB-001

Trial Locations

Location
Status
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Clinical Trial Site
Pittsburgh, Pennsylvania, United States, 15224
Status
N/A
Location
Clinical Trial Site
Nashville, Tennessee, United States, 37232
Status
N/A
Location
Clinical Trial Site
Seattle, Washington, United States, 98105
Status
N/A